Therapeutic potential of curcumin in prostate cancer - IV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells

Prostate

Volumn 60, Issue 1, 2004, Pages 1-17

  Dorai, Thambi ^a,c   Dutcher, Janice P ^a   Dempster, David W ^b   Wiernik, Peter H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Columbia Univ Coll of Phys/Surgs ^*  (United States)

^c OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

Bone metastasis; Curcumin; Prostate cancer; Tyrosine kinases

Indexed keywords

COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BONE METASTASIS; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CELL GROWTH; CELL STRAIN C4 2B; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; GENE ACTIVATION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MICROENVIRONMENT; MINERALIZATION; OSTEOBLAST; OSTEOCLAST; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL COMMUNICATION; CELL SURVIVAL; CURCUMIN; HUMANS; MALE; OSTEOBLASTS; PHENOTYPE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; TUMOR CELLS, CULTURED;

EID: 2442701479     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10359     Document Type: Article

References (86)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
2. Cher ML. Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 2001;11:483-488.
3. Isaacs JT. The biology of hormone refractory prostate cancer: Why does it develop? Urol Clin North Am 1999;26:263-273.
4. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen dependent cancer cells. Canecr J 2000;6:220-233.
5. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-573.
6. Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of Data. IARC Sci Publ 1992;120: 145-173.
7. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-131.
8. Mandel S, Schuman LM. Epidemiology of the cancer of the prostate. Rev Cancer Epidemiol 1980;1:1-65.
9. Boyle P, Kevi R, Lucchuni F, La Vecchia C. Trends in diet related cancers in Japan: A conundrum? Lancet 1993;342:752.
10. Hebert JR, Hurley TG, Olendszki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: A cross national study. J Natl Cancer Inst 1998; 90:1637-1647.
11. Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostatic disease. Eur J Urol 1999;35:377-387.
12. Clarke LC, Combs DR Jr., Turnbull BW. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276:1957-1963.
13. Gross C. Treatment of early recurrent prostate cancer with 1,25 dihydroxy vitamin D3. J Urol 1998;159:2035-2039.
14. Yip I, Heber D, Aronson W. Nutrition and prostate cancer. Urol Clin North Am 1999;26:403-411.
15. Morton MS, Griffiths K, Blacklock N. The preventive role of diet in prostatic disease. Br J Urol 1996;77:481-493.
16. Srimal RC, Dhawan BN. Pharmacology of diferuloylmethane (curcumin) a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 1973;25:447-452.
17. Toda S, Miyase T, Arichi H, Tanizawa H, Takino Y. Natural antioxidant III. Antioxidative componenets isolated from the rhizome of curcuma longa L. Chem Pharm Bull (Tokyo) 1985;33: 1725-1728.
18. Kellof JG. Strategy and planning for chemopreventive drug development: Clinical development plans: Curcumin. J Cell Biochem 1996;26S:54-71.
19. Azuine MA, Bhide SV. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical cacinogens in Swiss mice. Nutr Cancer 1992;17:77-83.
20. Rao CV, Rivenson A, Simi B, Reddy B. Chemoprevention of colon carcinogenesis by curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995;55:259-266.
21. Kawamori T, Lubert R, Steele VE, Kellof JG, Kaskey RB, Rao CV, Reddy BS. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999;59:597-601.
22. Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churcil MR, Martucci C, Newmark HL, Bertagnolli MM. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis (Lond) 2000;21: 921-927.
23. Reddy PAC, Lokesh BR. Studies on the inhibitory effect of curcumin and eugenol on the formation of reactive oxygen species and the oxidation of ferrous iron. Mol Cell Biochem 1994;37:1-8.
24. Singh S, Aggarwal BB. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270:24995-25000.
25. Huang MT, Lysz T, Ferraro T, Conney AH, Inhibitory effects of curcumin on in vitro lopoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991;51:813-819.
26. Samaha HS, Kellof GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenyl-3-methyl caffeate, and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention. Cancer Res 1997;57: 1301-1305.
27. Korutla L, Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A413 cells. Biochim Biopohys Acta 1994;1224:597-600.
28. neu. Clin Cancer Res 1999;5:1884-1891.
29. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer I Curcumin induces apoptosis in both androgen dependent and androgen independent prostate cancer cells. Prostate Cancer Prostatic Dis 2000;3:84-93.
30. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 2000;4:1-6.
31. Dorai T, Cao Y-C, Dorai B, Buttyan R, Katz A. Therapeutic potential of curcumin in human prostate cancer III. Curcumin inhibits proliferation, induceds apioptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001;47: 293-303.
32. Koeneman KS, Yeung F, Chung LWK. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-261.
33. Thalman GN, Sikes RA, Wu TT, Degeorges A, Chang S-M, Ozen M, Pathak S, Chung LWK. LNCaP progression model of human prostate cancer: Androgen independence and osseous metastasis. Prostate 2000;44:91-103.
34. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LWK. Establishing prostate cancer cell xenogfrafts in bone: Induction of the osteoblastic reaction by PSA producing tumors in athymic and SCID/bg mice using LNCaP and lineage derived metastatic sublines. Int J Cancer 1998;77:887-894.
35. Chung LWK. Prostate carcinoma bone stroma interaction and its biologic and therapeutic implications. Cancer (Suppl) 2003;97: 772-778.
36. Bellows CG, Ciaccia A, Heerche JN. Osteoprogenitor cells in cell populations derived from mouse and rat calvaria differ in their response to corticosterone, cortisol and cortisone. Bone 1998;23: 119-125.
37. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong W-X, Gelinas C, Rabson AB. Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate 2002;52:183-200.
38. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L. Inhibition of COX-2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of the NF-κB activation via the NIK/ IKK signaling complex. Oncogene 1999;18:6013-6020.
39. Russell JS, Raju U, Gumin GJ, Lanfg FF, Wilson DR, Huet T, Tofilon PJ. Inhibition of radiation induced nuclear factor κB activation by an anti-ras single chain antibody fragment: Lack of involvement in radiosensitization. Cancer Res 2002;62: 2318-2326.
40. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton M, Bubley G, Balk S. Tyrosine kinases expressed in vivo by human prostate cancer in vivo metastases and loss of type I insulin like growth factor receptor. Am J Pathol 1999;155: 1271-1279.
41. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cordo C. Changing patterns of expression of the epidermal growth factor receptor and transforming growth factor-alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995;1:545-550.
42. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002;1:507-514.
43. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnet LJ, Gescher AJ, Steward WP. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894-1900.
44. Deftos LJ. Prostate carcinoma: Production of bioactive factors. Cancer (Suppl) 2000;88:3002-3008.
45. Ide H, Seligson DB, Memarzadeh S, Xin L, Horvath S, Dubey P, Flick MB, Kacinski BM, Palotie A, Witte ON. Expression of CSF-1 factor receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci USA 2002;99:14404-14409.
46. Miyamoto T, Ohneda O, Arai F, Iwamoto K, Okada S, Takagi K, Anderson DM, Suda T. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001;98:2544-2554.
47. Lin D-L, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. Bone metastatic LNCaP derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47: 212-221.
48. Zhang J, Dai J, Qi Y, Lin D-L, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-1244.
49. Fu Z, Dozmorov IM, Keller ET. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells. Prostate 2002;51:10-20.
50. Yi B, Williams PJ, Niewolna M, Herling C, Mundy GR, Yoneda T. Evidence that osteolysis precedes osteoblastic lesions in a model of human osteoblastic metastasis. J Bone Miner Res 2000;15:S177.
51. Percival RC. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13:41-49.
52. Clarke N. The effects of pamidronate disodium treatment in metastatic prostate cancer. Rev Contemp Pharmacother 1998;9: 205-212.
53. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Exp 2000;10:159-178.
54. Cramer SD, Peehl DM, Edgar MG, Wong ST, Deftos LJ, Feldman D. Parathyroid hormone-related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate 1996;29:20-29.
55. Tovar Sepulveda VA, Falzon M. Regulation of PTH-related protein gene expression by vitamin D in PC-3 prostate cancer cells. Mol Cell Endocrinol 2002;190:115-124.
56. Brown JM, Corey E, Lee ZD, True LD, Bun TJ, Tondravi M, Vessella RL. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001;57:611-616.
57. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289:1504-1508.
58. Surh YJ, Han SS, Keum YS, Seo HJ, Lee SS. Inhibitory effects of curcumin and capsaicin on phorbol-ester induced activation of eukaryotic transcription factors NF-kappa B and AP-1. Biofactors 2000;12:107-112.
59. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20: 7597-7609.
60. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB. Curcumin blocks cytokine mediated NF-κB activation and proinflammatory gene expression by inhibiting the inhibitory factor I-kappa B kinase activity. J Immunol 1999;163:3474-3483.
61. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Annual Rev Immunol 2000;18: 621-663.
62. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 2003; 23:363-398.
63. Robinson D, He F, Pretlow T, Kung H-J. A tyrosine kinase profile of prostatic carcinoma. Proc Natl Acad Sci USA 1996;93:5958-5962.
64. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and to therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-2935.
65. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000; 42:150-160.
66. Wells A. Tumor invasion: Role of growth factor induced cell motility. Adv Cancer Res 2000;78:31-101.
67. Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB. Effect of epidermal growth factor on prostate cancer cell line PC-3 growth and invasion. Prostate 1994;24:46-53.
68. Kim S-J, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor signaling in tumor cells and tumor associated endothelial cells for therapy of androgen independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-1210.
69. Kascinski B. Expression of CSF-1 and its receptor CSF-1 R in non-hematopoietic neoplasms. Cancer Treat Res 2002;107:285-292.
70. Scher HI, Chung LWK. Bone metastases: biology and therapy. Semin Oncol 1994;21:630-656.
71. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997;80:1581-1587.
72. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS. Prostate carcinoma skeletal metastases: Cross talk between tumor and bone. Cancer Metastasis Rev 2001; 20:333-349.
73. Akimoto S, Okumura A, Fuse H. Relationship between serum levels of IL-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocrine J 1998;45:183-189.
74. Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Overproduction of parathyroid hormone related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer 1999;80:257-264.
75. Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T. Macrophage colony stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993;91:257-263.
76. Habib AA, Chatterjee S, Park SK, Ratan RR, Lefebvre S, Vartanian T. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-κB) inducing kinase to activate NF-kappa B. Identification of a novel receptor tyrosine kinase signalsome. J Biol Chem 2001;276: 8865-8874.
77. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. Cancer Lett 1999;141:159-165.
78. Lin L-I, Ke Y-F, Ko Y-C, Lin J-K. Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Lab Invest 1998;55: 349-353.
79. Arbiser JL, Klauber N, Rohan R, Leeuwen RV, Huang M-T, Fisher C, Flynn E, Byers HR. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998;4:376-383.
80. Andela VB, Schwarz EM, Puzas JE, O'Keefe RJ, Rosier RN. Tumor metastasis and reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappa B. Cancer Res 2000;60:6557-6562.
81. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastasis. Oncogene 2001;20:4188-4197.
82. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min do S, Chang JS, Jeong YJ, Lee YH, Park JW, Kwon TK. Molecular mechanisms of curcumin induced cytotoxicity: Induction of apoptosis through generation of recative oxygen species, down regulation of Bcl-XL, IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003;24:1199-1208.
83. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul A, Applebaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoptrotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273: 14363-14367.
84. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin is a survival factor for human prostate cancer cells. Cancer Res 2002;62:1619-1623.
85. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev Cancer 2002;2:584-593.
86. Goltzman D. Osteolysis and cancer. J Clin Invest 2001;107: 1219-1220.